Clinical performance of polymer-coated paclitaxel-eluting stent implanted for diffuse and calcified superficial femoral artery stenotic lesions: Insights from a patient on hemodialysis. (June 2021)

• Record Type: Journal Article
• Authors: Yoshioka, Naoki; Takagi, Kensuke; Tokuda, Takahiro; Morita, Yasuhiro; Morishima, Itsuro
• Is Part Of: SAGE open medical case reports. Volume 9(2021)
• Publication Date: 2021-06
• Subjects: Endovascular therapy -- polymer-coated paclitaxel-eluting stent -- interwoven nitinol stent -- long and calcified lesion -- patency; Clinical medicine -- Case studies -- Periodicals; 616.09
• DOI: 10.1177/2050313X211025929
• Languages: English
• ISSNs: 2050-313X

Abstract

In recent years, various devices have been approved for peripheral artery disease with femoropopliteal lesions. However, treatment of long, calcified, and diffused lesions is still challenging because these lesions are associated with restenosis. This report described the case of an 82-year-old man with bilateral severely calcified and diffused long lesions in the superficial femoral artery that was treated using polymer-coated paclitaxel-eluting stent and interwoven nitinol stent. After 6 months, in-stent restenosis was observed at the implantation site of the interwoven nitinol stents. Polymer-coated paclitaxel-eluting stents were deployed at the in-stent restenosis site. After another 6 months, angiography and intravascular ultrasound imaging revealed no restenosis at the polymer-coated paclitaxel-eluting stent site. Optical coherence tomography was also performed, revealing that the stent struts were well covered by neointima, which was very thin at approximately 0.1 mm. This representative case demonstrated substantial differences in the effects of devices; in other words, the superiority of polymer-coated paclitaxel-eluting stent in treating long, diffuse, and calcified lesions indicated that its implantation is a reasonable option when the initial gain was obtained following sufficient vessel preparation.